Search

Meet BioPredX, our new member. We spoke with Helena García Cebollada, CEO.

Accreditation for Good Laboratory Practice (GLP) in medical device biocompatibility studies enables TECNALIA to provide manufacturers and developers with greater regulatory assurance, reinforcing the

BePharma Institute, a school specialising in training for the pharmaceutical and cosmetic industry, held three in-person events in Madrid and Barcelona during May and June 2026, with the aim of

The ESSAD project will enable the secure sharing of socio-health information among the various stakeholders involved in the care of elderly and dependent people.

In 1920, the Spanish physician and humanist Gregorio Marañón popularised and adopted the phrase coined by Hippocrates: “There are no diseases, only patients.” It sounds simple, yet it has taken more

The United Kingdom will be the Guest Nation at BIOSPAIN 2026, underscoring the event’s growing international relevance. In this interview, Ceri Morgan, HM Trade Commissioner for Europe, shares the UK

ACCIÓ’s Noves Oportunitats de Negoci calls for proposals provide Catalan companies with a supportive framework for analysing and structuring new growth opportunities.

The EU EPSCO Council took a step forward in the legislative process of the Biotech Act I by agreeing on a common position regarding the proposed Directive, paving the way for negotiations with the

For AseBio, the agreement marks a significant step towards a modern, science-based regulatory framework capable of fostering innovation and addressing key challenges such as climate change

We interview Alfonso de Egaña Barrenechea, CEO of Molefy Pharma, a company developing AP-2, an innovative molecule designed to restore TDP-43 function and modify the course of the disease.

Rafael López, Head of Technology Transfer and Director of the PONS IP Office in Valencia.

We have contributed to the Fraunhofer Institute’s technical questionnaire on the Biotech Act II, the European Commission’s public consultation on this forthcoming legislative initiative, and the

The University of Barcelona Parc Científic de Barcelona (PCB-UB) broke its investment record in 2025, with a total of €229.7 million raised by the companies in its ecosystem. Start-ups, spin-offs and

Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.

Potential agreement follows positive clinical and stability data, supporting rollout in UK, Canada, Australia and New Zealand.